Clinical Trials Using CSF1R Inhibitor DCC-3014

Clinical trials are research studies that involve people. The clinical trials on this list are studying CSF1R Inhibitor DCC-3014. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

    This is a multicenter, open-label Phase 1 / 2 study of DCC-3014 in patients with malignant solid tumors and tenosynovial giant cell tumor (TGCT). There will be 2 distinct parts in this study: Dose Escalation (Phase 1) and Expansion (Phase 2). Phase 1 will enroll both malignant solid tumor and TGCT patients. Phase 2 will comprise two cohorts (Cohort A and Cohort B) and will only enroll TGCT patients.
    Location: 8 locations

  • DCC-3014 and Avelumab for the Treatment of Locally Advanced or Metastatic High-Grade Sarcoma

    This phase Ib trial studies the side effects and best dose of DCC-3014 and how well it works when given together with avelumab for the treatment of high-grade sarcoma that has spread to nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic). DCC-3014 may help fight cancer by targeting a type of white blood cell called a macrophage. Macrophages are immune cells that are present in or around tumors. Certain macrophages can block the body’s immune system from fighting cancer. Some tumors do not respond to immunotherapy drugs alone because of these macrophages. DCC-3014 may stop macrophages from blocking the immune system and may allow immunotherapy to stimulate the immune system to fight cancer. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving DCC-3014 and avelumab may help improve symptoms and shrink or stabilize cancer.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York